# Contents

**Highlights of This Issue** 2213

**REVIEW**

2215  
**New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects**  

**THERAPEUTIC DISCOVERY**

2224  
**Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells**  
Nicole Berdelle, Teodora Nikolova, Steve Quiros, Thomas Efferth, and Bernd Kaina

2234  
**Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: \( \text{In Vitro} \) and \( \text{Ex Vivo} \) Studies in Humans**  
Hyun-Seuk Moon, John P. Chamberland, Konstantinos Aronis, Sofia Tseleni-Balafouta, and Christos S. Mantzoros

2244  
**Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma**  
Cheri Cloninger, Andrew Bernath, Tariq Bashir, Brent Holmes, Nicholas Artinian, Teresa Ruegg, Lauren Anderson, Janine Masri, Alan Lichtenstein, and Joseph Gera

2257  
**Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved \( \alpha_4 \) Integrin Expression and a Compromised CAM-DR Phenotype**  
Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair, Rachid Baz, Mark L. McLaughlin, Anne E. Cress, and Lori A. Hazlehurst

**PRECLINICAL DEVELOPMENT**

2267  
**Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase \( \text{Mps1} \)**  
Keith D. Tardif, Aaron Rogers, Jared Cassiano, Bruce L. Roth, Daniel M. Cimbora, Rena McKinnon, Ashley Peterson, Thomas B. Douce, Rosann Robinson, Irene Dorweiler, Thaylon Davis, Mark A. Hess, Kirill Ostanin, Damon I. Papac, Vijay Baichwal, Ian McAlexander, J. Adam Willardsen, Michael Saunders, Hoarau Christophe, D. Vijay Kumar, Daniel A. Wettstein, Robert O. Carlson, and Brandi L. Williams

2276  
**Integrin \( \alpha_6^\text{high} \) Cell Population Functions as an Initiator in Tumorigenesis and Relapse of Human Liposarcoma**  
Lu Wang, Lingxian Wang, Yanhong Gu, Yongqian Shu, Yan Shen, and Qiang Xu

2287  
**Micelle-Encapsulated Thiostrepton as an Effective Nanomedicine for Inhibiting Tumor Growth and for Suppressing FOXM1 in Human Xenografts**  
Ming Wang and Andrei L. Gartel

2298  
**Cabozantinib (XL184), a Novel \( \text{MET} \) and \( \text{VEGFR2} \) Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth**  
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2309</td>
<td>Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer</td>
<td>Yixian Zhang, Stephen Castaneda, Melissa Dumble, Maoliang Wang, Mary Mileski, Zhengxing Qu, Steven Kim, Victoria Shi, Patricia Kraft, Ying Gao, Jenny Pak, Puja Sapra, Raj Bandaru, Hong Zhao, Robert L. Vessella, Ivan D. Horak, and Lee M. Greenberger</td>
</tr>
<tr>
<td>2320</td>
<td>The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice</td>
<td>Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A. Telfer, Nicola J. Curtin, and Kaye J. Williams</td>
</tr>
<tr>
<td>2330</td>
<td>Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity</td>
<td>Deliang Cao, Amy Ziembka, James McCabe, Ruiyan Yan, Laxiang Wan, Bradford Kim, Michael Gach, Stuart Flynn, and Giuseppe Pizzorno</td>
</tr>
<tr>
<td>2350</td>
<td>Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models</td>
<td>Jae-Ho Cheong, Eun Sung Park, Jiyoung Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Catherine Nguyen-Charles, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Murali Ravoori, Vikas Kundra, Jaffer Ajani, Ju-Seog Lee, Waun Ki Hong, and Gordon B. Mills</td>
</tr>
<tr>
<td>2363</td>
<td>Vitamin E δ-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-κB Activation in Pancreatic Cancer</td>
<td>Kazim Husain, Rony A. Francois, Teruo Yamauchi, Marta Perez, Said M. Sebti, and Mokenge P. Malafa</td>
</tr>
<tr>
<td>2373</td>
<td>The Novel Bcl-2 Inhibitor ABT-737 Is More Effective in Hypoxia and Is Able to Reverse Hypoxia-Induced Drug Resistance in Neuroblastoma Cells</td>
<td>Tetyana Klymenko, Martin Brandenburg, Christopher Morrow, Caroline Dive, and Gyu Makin</td>
</tr>
<tr>
<td>2377</td>
<td>The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice</td>
<td>Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A. Telfer, Nicola J. Curtin, and Kaye J. Williams</td>
</tr>
<tr>
<td>2405</td>
<td>Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity</td>
<td>Deliang Cao, Amy Ziembka, James McCabe, Ruiyan Yan, Laxiang Wan, Bradford Kim, Michael Gach, Stuart Flynn, and Giuseppe Pizzorno</td>
</tr>
<tr>
<td>2426</td>
<td>GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway</td>
<td>Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan, Megan Berry, Wei Wei Prior, Leslie Lee, John D. Lesnich, Cristina Lewis, Jim Nonomiy, Jodie Pang, Laurent Salphati, Alan G. Olivero, Daniel P. Sutherland, Carol Or'Brien, Jill M. Speorke, Sonal Patel, Letitia Lensun, Robert Kassees, Leanne Ross, Mark R. Lackner, Deepak Sampath, Marcia Belvin, and Lori S. Friedman</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Human lung microvascular cells cocultured with human diploid fibroblasts form extensive networks of tubules in response to VEGF that can be visualized by immunostaining for CD31, an endothelial cell marker. In the presence of cabozantinib (XL184), a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2, it was found that tubule formation was inhibited in the absence of cytotoxicity. Similarly, cabozantinib inhibited tubule formation in response to conditioned media derived from tumor cell cultures, suggesting that secreted tumor cell-derived proangiogenic growth factors are unable to circumvent inhibition of tubule formation by cabozantinib. For details, see article by Yakes and colleagues on page 2298.
Molecular Cancer Therapeutics

10 (12)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/10/12

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.